Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
PSMA-positive Metastatic Castration-Resistant Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), and Pheochromocytoma.
PSMA-positive Metastatic Castration-Resistant Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), and Pheochromocytoma.
PSMA-positive Metastatic Castration-Resistant Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), and Pheochromocytoma.
Approved for use in oncology care according to FDA-approved indications.
Maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, breast, pancreatic, and prostate cancer.
Advanced solid tumors and hematologic malignancies with matching genomic alterations.
Historic first-line treatment for Hodgkin Lymphoma (now primarily used in specific relapsed settings).
Locally advanced or metastatic Bladder / Urothelial Carcinoma.
HER2-overexpressing Breast Cancer, metastatic Gastric Cancer, and gastroesophageal junction adenocarcinoma.
HER2-overexpressing Breast Cancer, metastatic Gastric Cancer, and gastroesophageal junction adenocarcinoma.
Brain Tumors (Glioblastoma, Astrocytoma), Multiple Myeloma, Lymphomas, Leukemias, Sarcomas, and conditioning regimens.
Approved for use in oncology care according to FDA-approved indications.